Heart and Blood Diseases

Diseases and Abnormalities at or Before Birth

All Conditions

Nervous System Diseases

Neoplasms

Rare Diseases

Arteriovenous Malformations

Congenital Abnormalities

Intracranial Arteriovenous Malformations

Hemangioma

Vascular Malformations

Cardiovascular Abnormalities

Vascular Diseases

Neoplasms, Vascular Tissue

Neoplasms by Histologic Type

Cerebrovascular Disorders

Brain Diseases

Central Nervous System Diseases

Central Nervous System Vascular Malformations

Nervous System Malformations

Intracranial Arterial Diseases

Intracranial Arteriovenous Malformation

SQUID™

A non-interventional multicentric study for patients with a cerebral AVM for which endovascular treatment is indicated.

This observational study will collect data about the treatment of ruptured, unruptured, untreated or endovascular previously treated AVM's.

Primary endpoint is safety. Safety will be assessed with the number of procedure-related complications occurring during the endovascular treatment until 30 days after the final embolization.

Secondary endpoint is efficacy. Efficacy will be assessed by angiography and clinical outcome assessments (mRS).

For each patient enrolled, data will be collected at inclusion, at each embolization session and at 6 ± 1 months after the end of the endovascular treatment phase.

Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent

The safety is assessed with the number of procedure-related complications occurring during endovascular treatment until 30 days after the final embolization session. Procedure-related complications include complications/adverse events related to the procedure or to the device such as but not limited to hemorrhagic and ischemic complications.

Change of mRS score at 6 months after treatment phase is assessed compared to baseline mRS score.

The degree of the predefined targeted portion of the AVM's occlusion will be assessed angiographically.

Archer Research

Emboflu

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent	NCT02602990	Cerebral Arteri...	SQUID™	18 Years -	Emboflu
Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent	NCT02602990	Cerebral Arteri...	SQUID™	18 Years -	Emboflu

Spots Global Cancer Trial Database for squid™

Every month we try and update this database with for squid™ cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for squid™

Every month we try and update this database with for squid™ cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for squid™ cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.